Fruth, Briant

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial

Venook, A. P., Niedzwiecki, D., Lenz, H.-J., Innocenti, F., Fruth, B., Meyerhardt, J. A., Schrag, D., Greene, C., O'Neil, B. H., Atkins, J. N., et al. (2017) · JAMA

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 898

BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network study

Mettu, N. B., Twohy, E., Ou, F.-S., Halfdanarson, T. R., Lenz, H. J., Breakstone, R., Boland, P. M., Crysler, O., Wu, C., Grothey, A., et al. (2019) · Annals of Oncology

Colorectal Cancer Treatments and StudiesCancer Immunotherapy and Biomarkers

Cited by 72